Sarepta Therapeutics Inc (SRPT) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Summary

Sarepta Therapeutics Inc (Sarepta) is discovers and develops unique RNA-targeted therapeutics, gene therapy and other genetic medicine approaches to treat rare neuromuscular diseases. The company develops drugs based on its proprietary, highly-differentiated and innovative platform technology, phosphorodiamidate morpholino oligomer (PMO) chemistries. Its first commercial product, Exondys 51 is indicated for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. Sareptas key pipeline products using PMO chemistry includes Golodirsen to skip exon 53 of the DMD gene; and Casimersen to skip exon 45 of the DMD gene. Sarepta is headquartered in Cambridge, Massachusetts, the US.

Sarepta Therapeutics Inc (SRPT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 5
List of Figures 5
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Sarepta Therapeutics to Acquire Manufacturing Plant in Massachusetts from Eisai for USD15 Million 12
Partnerships 13
InVitae Expands Partnership with Sarepta Therapeutics 13
Sarepta Therapeutics Enters into Partnership with Myonexus Therapeutics 14
Sarepta Therapeutics Enters into Research Agreement with Duke University 15
Sarepta Therapeutics Enters into Research Agreement with Genethon 16
Sarepta Therapeutics Enters into Research Agreement with Nationwide Childrens Hospital 17
Catabasis Pharma Enters into Agreement with Sarepta Therapeutics 18
Murdoch University Enters into Research Agreement with Sarepta Therapeutics 19
Sarepta Therapeutics Enters into Agreement with Flagship Biosciences 20
Sarepta Therapeutics Enters Into Co-Development Agreement With University College London 21
Licensing Agreements 22
Sarepta Therapeutics Enters into Licensing Agreement with BioMarin Pharma 22
Sarepta Therapeutics Enters into Licensing Agreement with Nationwide Childrens Hospital 24
Sarepta Therapeutics Enters into Licensing Agreement with Summit Therapeutics 25
Sarepta Therapeutics Enters Into Licensing Agreement With University Of Western Australia For Duchenne Muscular Dystrophy 26
Equity Offering 28
Sarepta Therapeutics Prices Public Offering of Shares for USD325 Million 28
Sarepta Therapeutics Prices Public Offering of Shares for USD300 Million 30
Sarepta Therapeutics to Raise USD37.5 Million in Public Offering of Shares 32
Sarepta Therapeutics Raises USD126.8 Million in Public Offering of Shares 33
Sarepta Therapeutics Completes Public Offering Of Shares For US$100.7 Million 35
Sarepta Therapeutics Raises USD125 million in Public Offering Of Shares 37
Sarepta Therapeutics Completes Public Offering Of Common Stock For US$125 Million 38
Sarepta Therapeutics Completes Private Placement Of Shares 40
Debt Offering 41
Sarepta Therapeutics Announces Exercise of Initial Purchasers Option for USD95 Million in Private Placement of Notes Due 2024 41
Asset Transactions 42
Sarepta Therapeutics Sells Pediatric Disease Priority Review Voucher 42
Sarepta Therapeutics Inc - Key Competitors 43
Sarepta Therapeutics Inc - Key Employees 44
Sarepta Therapeutics Inc - Locations And Subsidiaries 45
Head Office 45
Other Locations & Subsidiaries 45
Recent Developments 46
Strategy And Business Planning 46
Jun 27, 2017: Sarepta Therapeutics Announces Grand Opening of its Research and Manufacturing Center at Andover 46
Financial Announcements 47
May 03, 2018: Sarepta Therapeutics Announces First Quarter 2018 Financial Results and Recent Corporate Developments 47
Mar 01, 2018: Sarepta Therapeutics Announces Fourth Quarter 2017 and Full-Year 2017 Financial Results and Recent Corporate Developments 50
Oct 25, 2017: Sarepta Therapeutics Announces Third Quarter 2017 Financial Results and Recent Corporate Developments 53
Jul 19, 2017: Sarepta Therapeutics Announces Second Quarter 2017 Financial Results and Recent Corporate Developments 55
Apr 27, 2017: Sarepta Therapeutics Announces First Quarter 2017 Financial Results and Recent Corporate Developments 57
Feb 28, 2017: Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2016 Financial Results and Recent Corporate Developments 59
Corporate Communications 61
Jun 07, 2018: Sarepta Therapeutics Appoints Gilmore ONeill, M.B., M.M.Sc. as Chief Medical Officer 61
Dec 05, 2017: Sarepta Therapeutics Elects Biopharmaceutical Veteran, Michael W. Bonney, to its Board of Directors 62
Sep 25, 2017: Sarepta Therapeutics Appoints Guriqbal S. Basi, Ph.D. as Chief Scientific Officer 63
Apr 05, 2017: Sarepta Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) 64
Apr 03, 2017: Sarepta Therapeutics Announces Appointment of Catherine Stehman-Breen, M.D., M.S. as Chief Medical Officer 65
Mar 30, 2017: Sarepta Therapeutics Announces Addition of Kenneth Fischbeck, M.D. and Matthew Wood M.D., Ph.D. to the Companys Strategic and Scientific Advisory Board 66
Government and Public Interest 67
Apr 10, 2018: Advocacy groups urge US government to lower price of costly DMD drug 67
Product News 68
11/07/2017: Sarepta Therapeutics Announces FDA Clearance of IND for the Companys PPMO Exon 51 Candidate, SRP-5051 68
09/06/2017: Sarepta Therapeutics Announces Positive Results in Its Study Evaluating Gene Expression, Dystrophin Production, and Dystrophin Localization in Patients with Duchenne Muscular Dystrophy (DMD) Amenable to Skipping Exon 53 Treated with Golodirsen (SRP-4053) 69
Product Approvals 71
Nov 03, 2017: Sarepta Therapeutics and Nationwide Childrens Hospital Announce U.S. Food and Drug Administration (FDA) Clearance of the IND Application for the GALGT2 Gene Therapy Program 71
Other Significant Developments 72
Jun 25, 2018: Decode Duchenne Announces 1,000th Patient Application 72
Appendix 73
Methodology 73
About GlobalData 73
Contact Us 73
Disclaimer 73

List Of Tables

List of Tables
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Sarepta Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Sarepta Therapeutics to Acquire Manufacturing Plant in Massachusetts from Eisai for USD15 Million 12
InVitae Expands Partnership with Sarepta Therapeutics 13
Sarepta Therapeutics Enters into Partnership with Myonexus Therapeutics 14
Sarepta Therapeutics Enters into Research Agreement with Duke University 15
Sarepta Therapeutics Enters into Research Agreement with Genethon 16
Sarepta Therapeutics Enters into Research Agreement with Nationwide Childrens Hospital 17
Catabasis Pharma Enters into Agreement with Sarepta Therapeutics 18
Murdoch University Enters into Research Agreement with Sarepta Therapeutics 19
Sarepta Therapeutics Enters into Agreement with Flagship Biosciences 20
Sarepta Therapeutics Enters Into Co-Development Agreement With University College London 21
Sarepta Therapeutics Enters into Licensing Agreement with BioMarin Pharma 22
Sarepta Therapeutics Enters into Licensing Agreement with Nationwide Childrens Hospital 24
Sarepta Therapeutics Enters into Licensing Agreement with Summit Therapeutics 25
Sarepta Therapeutics Enters Into Licensing Agreement With University Of Western Australia For Duchenne Muscular Dystrophy 26
Sarepta Therapeutics Prices Public Offering of Shares for USD325 Million 28
Sarepta Therapeutics Prices Public Offering of Shares for USD300 Million 30
Sarepta Therapeutics to Raise USD37.5 Million in Public Offering of Shares 32
Sarepta Therapeutics Raises USD126.8 Million in Public Offering of Shares 33
Sarepta Therapeutics Completes Public Offering Of Shares For US$100.7 Million 35
Sarepta Therapeutics Raises USD125 million in Public Offering Of Shares 37
Sarepta Therapeutics Completes Public Offering Of Common Stock For US$125 Million 38
Sarepta Therapeutics Completes Private Placement Of Shares 40
Sarepta Therapeutics Announces Exercise of Initial Purchasers Option for USD95 Million in Private Placement of Notes Due 2024 41
Sarepta Therapeutics Sells Pediatric Disease Priority Review Voucher 42
Sarepta Therapeutics Inc, Key Competitors 43
Sarepta Therapeutics Inc, Key Employees 44
Sarepta Therapeutics Inc, Other Locations 45
Sarepta Therapeutics Inc, Subsidiaries 45

List Of Figures

List of Figures
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Sarepta Therapeutics Inc (SRPT) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Sarepta Therapeutics Inc (Sarepta) is discovers and develops unique RNA-targeted therapeutics, gene therapy and other genetic medicine approaches to treat rare neuromuscular diseases. The company develops drugs based on its

USD 250 View Report

Sarepta Therapeutics Inc (SRPT) - Financial and Strategic SWOT Analysis Review

Sarepta Therapeutics Inc (SRPT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by

USD 125 View Report

Juno Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Juno Therapeutics Inc (Juno) is a clinical-stage company that develops novel cellular immunotherapies. The company formulates cell-based cancer immunotherapies based on platforms such as chimeric antigen receptor and high-affinity T

USD 250 View Report

Aquestive Therapeutics Inc (AQST) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Aquestive Therapeutics Inc (Aquestive Therapeutics) is a pharmaceutical company that discovers, develops and commercializes prescription drug products and a pipeline of prescription formulations. The company offers PharmFilm a drug delivery

USD 250 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available